Publication number: 20190256498
Abstract: The present invention provides novel crystalline form L1 of daclatasvir dihydrochloride wherein the diffraction peaks at 5.35, 6.04, 6.76, 8.65, 9.21, 10.35, 10.32, 10.75, 11.04, 11.66, 12.95, 13.56, 16.06, 18.11, 20.58, 22.18, 23.27±0.2 degree two theta in an X-ray diffraction pattern. The present invention provides novel crystalline form L2 of daclatasvir dihydrochloride wherein the diffraction peaks at 8.27, 9.54, 11.06, 13.61, 15.34, 19.01, 22.26, 23.24, 24.73, 25.35±0.2 degree two theta in an X-ray diffraction pattern. The present invention further provides process for preparation of crystalline forms L1 and L2 of daclatasvir dihydrochloride.
Type:
Application
Filed:
July 7, 2017
Publication date:
August 22, 2019
Inventors:
Palash SANPHUI, Radhakrishna Bhikaji SHIVDAVKAR, Gurvinder Pal SINGH, Purna Chandra RAY, Girij Pal SINGH, Vikas Ashokrao SADAPHAL, Lalitkumar Dilipising RAJPUT, Hemraj Mahadeorao LANDE
Patent number: 10251850
Abstract: The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
April 9, 2019
Assignee:
LUPIN LIMITED
Inventors:
Pankaj Ramchandra Chaudhari, Sukhdeo Sampat Gunjal, Raju Muktaji Walunj, Anurag Trivedi, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh